Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Enrolling by invitation Observational

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

NCT04816773 · tracked via the Priya Life Science USA tracker
Phase
Observational
Started
2022-01-27
Last updated
2024-03-20

Condition(s) studied

Joint DiseasesOsteoarthritisArthritis KneeAvascular Necrosis

Investigational drug(s) / intervention(s)

EVOLUTION® NitrX™

EVOLUTION® NitrX™: EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Study summary

MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.

Eligibility

Sex
ALL
Min age
21 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Has previously undergone or currently has determined to undergo a primary TKA with the specified combination of components: EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert 2. Has previously undergone or currently has determined to undergo a primary TKA for any of the following: * non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis; * inflammatory degenerative joint disease including rheumatoid arthritis; * correction of functional deformity; 3. Willing to voluntarily sign the informed consent form 4. Willing and able to comply with the protocol, able to read and complete the required forms, and willing and able to adhere to the requirements of the protocol through the 10-year postoperative follow-up visit. 5. Previously implanted subjects must be enrolled within 14 months of their primary TKA implantation. Prospective enrollment of a previously unimplanted contralateral knee is permitted in this study provided: 1. the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) are used, 2. all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4. the subject agrees to a second Informed Consent document and data collection specific to the second TKA. Bilateral subjects can have both TKAs enrolled in the study provided: 1. the specified combination of components (EVOLUTION® NitrX™ CS/CR Non-Porous Femur, EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® CS Tibial Insert) were implanted in both, 2. all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3. enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4. the subject agrees to a second Informed Consent document and data collection specific to the second TKA. Bilateral implantation can occur at different time periods for the same subject. Exclusion Criteria: 1. Skeletally immature (less than 21 years of age) at time of implantation 2. Has or had an overt infection at the time of implantation 3. Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation 4. Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation 5. Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable 6. Currently enrolled in another clinical investigation which could affect the endpoints of this protocol 7. Has documented substance abuse issues 8. Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study 9. Currently incarcerated or has impending incarceration 10. Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol

Primary outcome measure(s)

  • Component Survivorship of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia — 10 years post-operative
    The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year
  • Component Survivorship of the EVOLUTION® NitrX™ CS/CR Non-Porous Femur — 10 years post-operative
    The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ CS/CR Non-Porous Femur out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.
  • Component Survivorship of the EVOLUTION® NitrX™ MP CS tibial inserts — 10 years post-operative
    The primary endpoint is to evaluate component survivorship of the EVOLUTION® NitrX™ MP CS tibial inserts out to 10 years follow-up. Percentage of knees survived with no revisions or replacement at 10-year.

Trial sites (2)

FacilityCityRegionStatus
Sah Orthopaedic Associates Fremont California
MSK Doctors, The Keep Clinic Grantham Lincolnshire
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04816773 on ClinicalTrials.gov ↗ ← All trials in the USA